“Phase 3 Trial Demonstrates Superior Patient Treatment Convenience of MC2-01 Calcipotriene Plus Betamethasone Dipropionate Cream Compared to Current Topical Suspension” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s62. doi:10.25251/skin.4.supp.61.